Variant · Snv

AKT1 E17K

CI-VAR-00000677Explore in graph →NP_001014432.1:p.Glu17LysNM_001014432.1:c.49G>AClinVar 13983 CIViC 4 rs121434592 rs34409589

Curated evidence

Evidence by cancer (8 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–8 of 8 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm2
AKT1 E17K	Akt Inhibitor MK2206	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID231 Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations. PMID 23888070 · Beaver et al., 2013 · Open in CIViC	civic
AKT1 E17K	Capivasertib	Predictive	C	Supports Sensitivity Response	3	accepted	EID709 In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been publishe… (full text at CIViC) PMID 26351323 · Davies et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13983	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Breast adenocarcinoma; Carcinoma of colon; Ovarian neoplasm; Proteus syndrome; Cowden syndrome 6; Neoplasm; Meningioma; Medulloblastoma SHH activated and TP53 wild-type; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype	germline/somatic	9	Apr 15, 2026

Melanoma3
AKT1 E17K	Vemurafenib	Predictive	D	Supports Resistance	1	accepted	EID4029 In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to ve… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
AKT1 E17K AND BRAF V600E	Uprosertib	Predictive	D	Supports Sensitivity Response	2	accepted	EID707 A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study. PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic
AKT1 E17K AND BRAF V600E	Dabrafenib + UprosertibCombination	Predictive	D	Supports Sensitivity Response	2	submitted	EID13115 A BRAF V600E-positive melanoma cell line (M262) with AKT E17K mutation was found to have a similar level of sensitivity to combination dabrafenib plus AKT inhibitor GSK2141795B (IC50 < 1nM) as to dabr… (full text at CIViC) PMID 24735930 · Lassen et al., 2014 · Open in CIViC	civic

Melanoma3

AKT1 E17K

Vemurafenib

Predictive

Supports Resistance

accepted

EID4029

In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to ve… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

civic

AKT1 E17K AND BRAF V600E

Uprosertib

Predictive

Supports Sensitivity Response

accepted

EID707

A melanoma cell line (M262) with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B in this study.

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

civic

AKT1 E17K AND BRAF V600E

Dabrafenib + UprosertibCombination

Predictive

Supports Sensitivity Response

submitted

EID13115

A BRAF V600E-positive melanoma cell line (M262) with AKT E17K mutation was found to have a similar level of sensitivity to combination dabrafenib plus AKT inhibitor GSK2141795B (IC50 < 1nM) as to dabr… (full text at CIViC)

PMID 24735930 · Lassen et al., 2014 · Open in CIViC

civic

HER2 Negative Breast Cancer1unmapped disease
AKT1 E17K	Capivasertib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	3	submitted	EID12181 In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC	civic

HER2 Negative Breast Cancer1unmapped disease

AKT1 E17K

Capivasertib + FulvestrantCombination

Predictive

Supports Sensitivity Response

submitted

EID12181

In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC)

PMID 37256976 · Turner et al., 2023 · Open in CIViC

civic